| Primary information |
|---|
| sequence ID | Seq_8091 |
| Peptide sequence | TAVVTNPKE |
| CancerPDF_ID | CancerPDF_ID9899, CancerPDF_ID12380, CancerPDF_ID13937, |
| PMID | 21533267,26992070,20974924 |
| Protein Name | Transthyretin,Transthyretin,Transthyretin |
| UniprotKB Entry Name | TTHY_HUMAN,A6XGL1_HUMAN,TTHY_HUMAN |
| Fluid | Serum,Serum,Plasma |
| M/Z | 479.76,NA,958.521 |
| Charge | 2,NA,2 |
| Mass (in Da) | NA,958.5226916,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | LC/MS/MS,LC-MS/MS,LC-MS/MS |
| Quantification Technique | Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | 1.49,FDR 1 %,NA |
| CancerPDF_ID | CancerPDF_ID9899, CancerPDF_ID12380, CancerPDF_ID13937, |
| p-Value | NA,NA,NA |
| Software | MASCOT,SEQUEST and Maxquant,MASCOT and SEQUEST |
| Length | 9,9,NA |
| Cancer Type | Lung adenocarcinoma,Melanoma,"Multiple myeloma patients, Acute myeloid leukemia" |
| Database | Swissprot Database (57.4),SwissProt Database,Uniprot database |
| Modification | NA,NA,NA |
| Number of Patients | 62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples,NA |
| Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples.",NA |
| Validation | MRM-based validation of 19 candidates,na,NA |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 181253
439049
|